Paper34367136
The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors.
Wang M and 6 others. Front Immunol, 2021. Cited by 126 papers, by iCite.
Cite this record
ConductScience Library. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Papers, record 34367136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34367136
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers | Major topic |
| Cytokines | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Animals | |
| Humans |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07249060 | Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients | Background |
Source ClinicalTrials.gov
References145
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29093678 | Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/29093678 | PubMed |
| 2 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 3 | 29443960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 4 | 29598848 | Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors? | Trends Immunol | 2018 | https://conductscience.org/library/papers/29598848 | PubMed |
| 5 | 34031618 | Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. | Nat Immunol | 2021 | https://conductscience.org/library/papers/34031618 | PubMed |
| 6 | 7566090 | Induction of apoptosis in mature T cells by tumour necrosis factor. | Nature | 1995 | https://conductscience.org/library/papers/7566090 | PubMed |
| 7 | 27885276 | Immunoregulation by members of the TGFβ superfamily. | Nat Rev Immunol | 2016 | https://conductscience.org/library/papers/27885276 | PubMed |
| 8 | 9636188 | Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9636188 | PubMed |
| 9 | 26406148 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406148 | PubMed |
| 10 | 26380086 | Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. | J Immunother Cancer | 2015 | https://conductscience.org/library/papers/26380086 | PubMed |
| 11 | 18503261 | Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. | Cancer Immun | 2008 | https://conductscience.org/library/papers/18503261 | PubMed |
| 12 | 12732663 | Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. | J Exp Med | 2003 | https://conductscience.org/library/papers/12732663 | PubMed |
| 13 | 27157491 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27157491 | PubMed |
| 14 | 27348007 | The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. | Vaccines (Basel) | 2016 | https://conductscience.org/library/papers/27348007 | PubMed |
| 15 | 30339766 | The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. | Am J Respir Crit Care Med | 2019 | https://conductscience.org/library/papers/30339766 | PubMed |
| 16 | 31043740 | Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. | Nature | 2019 | https://conductscience.org/library/papers/31043740 | PubMed |
| 17 | 1103152 | An endotoxin-induced serum factor that causes necrosis of tumors. | Proc Natl Acad Sci U S A | 1975 | https://conductscience.org/library/papers/1103152 | PubMed |
| 18 | 31664934 | Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. | BMC Cancer | 2019 | https://conductscience.org/library/papers/31664934 | PubMed |
| 19 | 28939128 | Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. | J Thorac Oncol | 2017 | https://conductscience.org/library/papers/28939128 | PubMed |
| 20 | 10688256 | Cytokines and their receptors: an overview. | Ther Drug Monit | 2000 | https://conductscience.org/library/papers/10688256 | PubMed |
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 126 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985639 | Long non-coding RNA prompts immune-related adverse events risk and immunotherapy response in pan-cancer. | iScience | 2026 | https://conductscience.org/library/papers/42985639 | PubMed |
| 42799102 | A Case Series of Raynaud's Phenomenon in the Setting of Immune Checkpoint Inhibitors. | J Immunother Precis Oncol | 2026 | https://conductscience.org/library/papers/42799102 | PubMed |
| 42756887 | Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42756887 | PubMed |
| 42732396 | Severe Immune-Related Adverse Events Associated with Durable Antitumor Responses Following Immune Checkpoint Inhibitor Therapy: Two Case Reports. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/42732396 | PubMed |
| 42582583 | Baseline IL-6, IL-8, IFN-ω, and perforin as prognostic biomarkers in immune checkpoint inhibitor-treated metastatic non-small cell lung cancer. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42582583 | PubMed |
| 42501206 | A baseline systemic inflammatory signature predicts anti-PD-1 response in advanced melanoma. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42501206 | PubMed |
| 42344718 | Long-term survival with tocilizumab treatment for tislelizumab-related pneumonitis in a patient with non-small cell lung cancer: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42344718 | PubMed |
| 42192983 | In-Treatment Kinetics of Peripheral Blood Immune Markers in PD-L1 High Non-Small Cell Lung Cancer and Prognostic Relevance for Immunotherapy Outcomes. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42192983 | PubMed |
| 42135662 | Single-cell and machine learning reveal ROS-associated heterogeneity in hepatocellular carcinoma for precision medicine. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42135662 | PubMed |
| 42133231 | Immunological Drug-Drug Interactions in Immune Checkpoint Inhibitor Therapy: Mechanisms, Clinical Evidence, and Artificial Intelligence. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42133231 | PubMed |
| 42118587 | IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42118587 | PubMed |
| 42093111 | Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti-PD-1 Therapy. | Immun Inflamm Dis | 2026 | https://conductscience.org/library/papers/42093111 | PubMed |
| 41992363 | Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape. | Biomark Res | 2026 | https://conductscience.org/library/papers/41992363 | PubMed |
| 41836401 | Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects. | Front Immunol | 2026 | https://conductscience.org/library/papers/41836401 | PubMed |
| 41775992 | In-depth Evaluation of the Olink Target 48 Cytokine Panel: Inter-Laboratory Evaluation of Performance and Reliability for Biomarker Studies in Oncology. | AAPS J | 2026 | https://conductscience.org/library/papers/41775992 | PubMed |
| 41751379 | Periodontitis-Induced Immune Reprogramming: Implications for Cancer Immunotherapy Response. | Biomedicines | 2026 | https://conductscience.org/library/papers/41751379 | PubMed |
| 41740058 | Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41740058 | PubMed |
| 41727433 | Impact of immune-related adverse events on treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors. | Front Immunol | 2026 | https://conductscience.org/library/papers/41727433 | PubMed |
| 41591497 | Metabolic syndrome and immune-related adverse events. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/41591497 | PubMed |
| 41470133 | Sleep Quality and Its Determinants Among Patients with Metastatic Cancer Treated with Immune Checkpoint Inhibitors: A Two-Center Cross-Sectional Study. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41470133 | PubMed |
Genes58
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34367136
GET https://conductscience.org/api/papers/v1/34367136/references?page=2